BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 23336594)

  • 1. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study.
    Artini PG; Di Berardino OM; Papini F; Genazzani AD; Simi G; Ruggiero M; Cela V
    Gynecol Endocrinol; 2013 Apr; 29(4):375-9. PubMed ID: 23336594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome.
    Genazzani AD; Lanzoni C; Ricchieri F; Jasonni VM
    Gynecol Endocrinol; 2008 Mar; 24(3):139-44. PubMed ID: 18335328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
    Genazzani AD; Prati A; Santagni S; Ricchieri F; Chierchia E; Rattighieri E; Campedelli A; Simoncini T; Artini PG
    Gynecol Endocrinol; 2012 Dec; 28(12):969-73. PubMed ID: 22612517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome.
    Genazzani AD; Battaglia C; Malavasi B; Strucchi C; Tortolani F; Gamba O
    Fertil Steril; 2004 Jan; 81(1):114-9. PubMed ID: 14711553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
    Pizzo A; Laganà AS; Barbaro L
    Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
    Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
    Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both.
    Genazzani AD; Prati A; Marchini F; Petrillo T; Napolitano A; Simoncini T
    Gynecol Endocrinol; 2019 Dec; 35(12):1088-1093. PubMed ID: 31304823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
    Wu J; Zhu Y; Jiang Y; Cao Y
    Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA; Shin SY; Yoon BK; Choi D
    Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol.
    Laganà AS; Barbaro L; Pizzo A
    Arch Gynecol Obstet; 2015 May; 291(5):1181-6. PubMed ID: 25416201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome.
    Zacchè MM; Caputo L; Filippis S; Zacchè G; Dindelli M; Ferrari A
    Gynecol Endocrinol; 2009 Aug; 25(8):508-13. PubMed ID: 19551544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial.
    Costantino D; Minozzi G; Minozzi E; Guaraldi C
    Eur Rev Med Pharmacol Sci; 2009; 13(2):105-10. PubMed ID: 19499845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
    Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
    Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
    Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
    Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
    J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of women with PCOS using myo-inositol and folic acid. New clinical data and review of the literature.
    Regidor PA; Schindler AE; Lesoine B; Druckman R
    Horm Mol Biol Clin Investig; 2018 Mar; 34(2):. PubMed ID: 29498933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a case-control study.
    Singh S; Akhtar N; Ahmad J
    Diabetes Metab Syndr; 2012; 6(4):207-11. PubMed ID: 23199540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
    Song J; Shen H; Li J; Huang Z; Zhang Y
    Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
    Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
    Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma level of calcitonin gene-related peptide in patients with polycystic ovary syndrome and its relationship to hormonal and metabolic parameters.
    Zhang Z; Gong F; Lu GX
    Peptides; 2012 Apr; 34(2):343-8. PubMed ID: 22314079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.